Last reviewed · How we verify

Leuprolide (GnRH agonists) — Competitive Intelligence Brief

Leuprolide (GnRH agonists) (Leuprolide (GnRH agonists)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology; Endocrinology.

marketed GnRH agonist GnRH receptor (GNRHR) Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Leuprolide (GnRH agonists) (Leuprolide (GnRH agonists)) — University of Pisa. Leuprolide is a GnRH agonist that initially stimulates, then suppresses gonadotropin release, leading to decreased testosterone and estrogen production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Leuprolide (GnRH agonists) TARGET Leuprolide (GnRH agonists) University of Pisa marketed GnRH agonist GnRH receptor (GNRHR)
Triptorelin (GnRH agonists) Triptorelin (GnRH agonists) University of Pisa marketed GnRH agonist GnRH receptor (GNRHR)
Triptorelin pamoate(15mg) Triptorelin pamoate(15mg) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University marketed GnRH agonist GnRH receptor
GnRH agonist trigger GnRH agonist trigger Rambam Health Care Campus marketed GnRH agonist GnRH receptor
Zoladex and Casodex Zoladex and Casodex AstraZeneca marketed GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex) GnRH receptor (Zoladex); androgen receptor (Casodex)
TRIPTORELIN ACETATE, hCG TRIPTORELIN ACETATE, hCG HaEmek Medical Center, Israel marketed GnRH agonist GnRH receptor
GnRH agonist/antagonist GnRH agonist/antagonist Memorial Sloan Kettering Cancer Center marketed GnRH agonist/antagonist GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH agonist class)

  1. Takeda · 4 drugs in this class
  2. Abbott · 3 drugs in this class
  3. Ipsen · 3 drugs in this class
  4. Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
  5. University of Pisa · 2 drugs in this class
  6. Chong Qing Reproducive and Genetic Institute · 1 drug in this class
  7. Chesapeake Urology Research Associates · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Enteris BioPharma Inc. · 1 drug in this class
  10. Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leuprolide (GnRH agonists) — Competitive Intelligence Brief. https://druglandscape.com/ci/leuprolide-gnrh-agonists. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing